PHAL: Net loss narrowed, Phal-501 advanced, and major rights issue to fund clinical trials in 2025

About this update from Pharmalundensis Ab

PharmaLundensis reported no revenue and a reduced net loss for 2024, advanced its Phal-501 drug candidate with positive patent and animal test results, and is pursuing a major rights issue to fund clinical trials and capitalize on Cleantech opportunities. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmalundensis Ab